Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucie Laot

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement|September 28, 2012
[Addictive behaviors in the aged]Philippe Nubukpo, Lucie Laot, Jean-Pierre Clément
Cancers|December 11, 2022
Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to <i>BRCA</i> Pathogenic Variant Carriers?Lucie Laot, Charlotte Sonigo, Julie Nobre, et al.
Journal of Assisted Reproduction and Genetics|May 8, 2023
Knowledge, acceptability and personal attitude toward pre-implantation 1 genetic testing (PGT) and pre-natal diagnosis (PND) for females carrying BRCA pathogenic variant according to fertility preservation experienceTraicie Dervin, Noémie Ranisavjevic, Lucie Laot, et al.
Cancers|February 11, 2023
Response to Ovarian Stimulation for Urgent Fertility Preservation before Gonadotoxic Treatment in <i>BRCA</i>-Pathogenic-Variant-Positive Breast Cancer PatientsLina El Moujahed, Robin Philis, Michael Grynberg, et al.
Cancers|January 27, 2021
<i>HER2</i>-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab RegimensEnora Laas, Arnaud Bresset, Jean-Guillaume Féron, et al.
Cancers|January 9, 2021
The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer SubtypesLucie Laot, Enora Laas, Noemie Girard, et al.
Plos One|June 25, 2020
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapyAnne-Sophie Hamy, Lauren Darrigues, Enora Laas, et al.
Cancers|October 15, 2020
No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and PrognosisVanille Simon, Lucie Laot, Enora Laas, et al.
Cancers|December 11, 2020
Impact of <i>BRCA</i> Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant ChemotherapyBeatriz Grandal, Clémence Evrevin, Enora Laas, et al.
Cancers|June 10, 2022
The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS)Elise Dumas, Lucie Laot, Florence Coussy, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement|September 28, 2012
[Addictive behaviors in the aged]Philippe Nubukpo, Lucie Laot, Jean-Pierre Clément
Cancers|December 11, 2022
Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to <i>BRCA</i> Pathogenic Variant Carriers?Lucie Laot, Charlotte Sonigo, Julie Nobre, et al.
Journal of Assisted Reproduction and Genetics|May 8, 2023
Knowledge, acceptability and personal attitude toward pre-implantation 1 genetic testing (PGT) and pre-natal diagnosis (PND) for females carrying BRCA pathogenic variant according to fertility preservation experienceTraicie Dervin, Noémie Ranisavjevic, Lucie Laot, et al.
Cancers|February 11, 2023
Response to Ovarian Stimulation for Urgent Fertility Preservation before Gonadotoxic Treatment in <i>BRCA</i>-Pathogenic-Variant-Positive Breast Cancer PatientsLina El Moujahed, Robin Philis, Michael Grynberg, et al.
Cancers|January 27, 2021
<i>HER2</i>-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab RegimensEnora Laas, Arnaud Bresset, Jean-Guillaume Féron, et al.
Cancers|January 9, 2021
The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer SubtypesLucie Laot, Enora Laas, Noemie Girard, et al.
Plos One|June 25, 2020
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapyAnne-Sophie Hamy, Lauren Darrigues, Enora Laas, et al.
Cancers|October 15, 2020
No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and PrognosisVanille Simon, Lucie Laot, Enora Laas, et al.
Cancers|December 11, 2020
Impact of <i>BRCA</i> Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant ChemotherapyBeatriz Grandal, Clémence Evrevin, Enora Laas, et al.
Cancers|June 10, 2022
The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS)Elise Dumas, Lucie Laot, Florence Coussy, et al.
Pageof 2